ipopba INmune Bio, Inc. (NASDAQ:INMB) is a clinical-stage biotechnology company developing immunotherapies for cancer and neuroinflammatory conditions like Alzheimer's disease [AD]. The DN-TNF platform targets soluble TNF, reducing inflammation without disrupting beneficial transmembrane TNF functions crucial for immune regulation and neuroprotection. The NK priming platform improves NK cells' ability to identify and eliminate abnormal cells, transforming them into highly functional, memory-like NK cells. I ...

INmune Bio, Inc. (NASDAQ:INMB) Q1 2024 Results Conference Call May 9, 2024 4:30 PM ET Company Participants David Moss - Chief Financial Officer Dr. RJ Tesi - Chief Executive Officer and Co-Founder Dr. Mark Lowdell - Chief Scientific Officer Conference Call Participants Tom Shrader - BTIG Joel Beatty - Baird Jason McCarthy - Maxim Group Daniel Carlson - Tailwinds Research Operator Greetings and welcome to the INmune Bio First Quarter 2024 Earnings Call. At the end of the presentation, there will be a questio ...

Exhibit 99.2 INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update Company to Host Conference Call Today, May 9, at 4:30pm ET BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical- stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended March 31, 2024 and provides a business update. Q1 2024 and Rece ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38793 INMUNE BIO INC. (Exact name of registrant as specified in its charter) (State of incorporation) (I.R.S. Employer Identification No.) 225 NE Mizner Blvd., S ...

Boca Raton, Florida, April 25, 2024 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced today that it has entered into definitive agreements for the sale and purchase of 986,000 shares of its common stock and warrants to purchase up to an aggregate of 986,000 shares of its common stock at an offering price of $9.84 per share of common stock a ...

Boca Raton, Florida, April 23, 2024 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, is delighted to announce the successful completion of the extended stability validation for XProTM continuous storage in solution at 2-8C. The 24 and 30-month stability test samples passed all chemistry and potency assays; allowing the Company to make a conservative claim ...

picturegarden/DigitalVision via Getty Images Topline Summary and Update INmune Bio (NASDAQ:INMB) is a company focused on developing drugs in two different disease areas: neurology and cancer medicine. I've previously covered this company in two articles, and I was a cautious optimist in my latest outing, with main reservations related to their cash burn rate and the challenges of developing drugs for Alzheimer disease, which is their most advanced focus. This article is an update providing a picture of ...

Exhibit 99.1 INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update Company to Host Conference Call Today, March 28, at 4:30pm ET BOCA RATON, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical- stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the year ended December 31, 2023 and provides a business update. Q4 2023 and ...

INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Conference Call March 28, 2024 4:30 PM ET Company Participants RJ Tesi - Chief Executive Officer David Moss - Chief Financial Officer Mark Lowdell - Chief Scientific Officer Conference Call Participants Joel Beatty - Baird Daniel Carlson - Tailwinds Research Operator Ladies and gentlemen, greetings and welcome to the INmune Bio Fourth Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-38793 INMUNE BIO INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organ ...